Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
This often involves improving nutritional intake, supporting overall health, and introducing treatments that encourage follicles to return to the growth phase
GLP-1 receptor agonists, like semaglutide and tirzepatide, could be a game-changer in reducing cardiovascular disease in this vulnerable group
Research use differs from medical use because a laboratory or preclinical study does not establish an approved human treatment
PLoS ONE 10:e0126978
Peer review Peer review information Nature Chemistry thanks the anonymous reviewers for their contribution to the peer review of this work
US$ 20.22
US$ 29.09
:max_bytes(150000):strip_icc()/GettyImages-1259158436-1a2fd7f2794d4b4a9bedca6422346548.jpg)
US$ 28.27
US$ 22.45
US$ 29.40
